Prenatal screening and perinatal HIV transmission in Northern Alberta, 1999-2006

Am J Public Health. 2009 Oct;99 Suppl 2(Suppl 2):S412-6. doi: 10.2105/AJPH.2007.133306. Epub 2009 Apr 16.

Abstract

Objectives: We evaluated the effectiveness of a program that includes routine opt-out prenatal HIV screening, combination antiretroviral therapy (ART), and a multidisciplinary team in preventing perinatal HIV transmission.

Methods: A retrospective analysis was performed on HIV-infected pregnant women in northern Alberta, Canada, who delivered between January 1, 1999, and February 28, 2006.

Results: Ninety-eight women had 113 deliveries. Forty-three percent were diagnosed with HIV infection through prenatal screening. Approximately 60% of HIV-infected pregnant women were Aboriginal, with 45% reporting alcohol use and 42% illicit drug use during pregnancy. The use of combination ART during pregnancy increased throughout the study period; 89% or more received combination ART from 2004 through 2006. Only 1 of the 111 infants (0.9%) was confirmed to be HIV infected, and that infant was born to a woman with no prenatal care.

Conclusions: High rates of HIV testing using an opt-out approach, combined with efforts by a multidisciplinary team, resulted in a low rate of perinatal HIV transmission in our cohort. The added value of retesting high-risk women late in pregnancy or with rapid HIV tests at the time of delivery should be explored.

MeSH terms

  • Adolescent
  • Adult
  • Alberta / epidemiology
  • Anti-Retroviral Agents / therapeutic use*
  • Cohort Studies
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / transmission*
  • Humans
  • Indians, North American
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Male
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / epidemiology
  • Pregnancy Complications, Infectious / virology
  • Prenatal Diagnosis*
  • Prevalence
  • Retrospective Studies
  • Young Adult

Substances

  • Anti-Retroviral Agents